EMA Authorised: Metalyse (tenecteplase) — Boehringer Ingelheim International GmbH

View source ↗

Summary

EMA authorised Metalyse (tenecteplase) for treatment in myocardial infarction with Boehringer Ingelheim as the MAH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction

Drugs mentioned

• Metalyse (tenecteplase)

Snippet

Status: Authorised. Therapeutic area: Myocardial Infarction. MAH: Boehringer Ingelheim International GmbH. Decision date: 20/07/2026